Literature DB >> 21339759

Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance.

V Grossmann, A Kohlmann, C Eder, C Haferlach, W Kern, N C P Cross, T Haferlach, S Schnittger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21339759     DOI： 10.1038/leu.2011.10

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  58 in total

Review 1.  Treatment advances for pediatric and adult onset neoplasms with monocytosis.

Authors:  Kristen B McCullough; Alexis K Kuhn; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2021-03-16       Impact factor: 3.952

2.  High-throughput molecular diagnosis of von Willebrand disease by next generation sequencing methods.

Authors:  Irene Corrales; Susana Catarino; Júlia Ayats; David Arteta; Carmen Altisent; Rafael Parra; Francisco Vidal
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

3.  Digital quantitation of potential therapeutic target RNAs.

Authors:  David W Dodd; Keith T Gagnon; David R Corey
Journal:  Nucleic Acid Ther       Date:  2013-05-08       Impact factor: 5.486

4.  Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Authors:  M Jawhar; J Schwaab; S Schnittger; K Sotlar; H-P Horny; G Metzgeroth; N Müller; S Schneider; N Naumann; C Walz; T Haferlach; P Valent; W-K Hofmann; N C P Cross; A Fabarius; A Reiter
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

Review 5.  Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease.

Authors:  Jill S Butler; Evangelia Koutelou; Andria C Schibler; Sharon Y R Dent
Journal:  Epigenomics       Date:  2012-04       Impact factor: 4.778

Review 6.  Genetics of MDS.

Authors:  Seishi Ogawa
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

7.  Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.

Authors:  Susanne Schnittger; Ulrike Bacher; Tamara Alpermann; Andreas Reiter; Madlen Ulke; Frank Dicker; Christiane Eder; Alexander Kohlmann; Vera Grossmann; Andreas Kowarsch; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

8.  Antibiotic treatment ameliorates Ten-eleven translocation 2 (TET2) loss-of-function associated hematological malignancies.

Authors:  Hongxiang Zeng; Hailan He; Lei Guo; Jia Li; Minjung Lee; Wei Han; Anna G Guzman; Shengbing Zang; Yubin Zhou; Xiaotian Zhang; Margaret A Goodell; Katherine Y King; Deqiang Sun; Yun Huang
Journal:  Cancer Lett       Date:  2019-09-26       Impact factor: 8.679

Review 9.  Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

Authors:  Dorothée Selimoglu-Buet; Eric Solary
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

10.  Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.

Authors:  Veronica Bernard; Niklas Gebauer; Thomas Dinh; Judith Stegemann; Alfred C Feller; Hartmut Merz
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.